var data={"title":"Epidermodysplasia verruciformis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Epidermodysplasia verruciformis</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/contributors\" class=\"contributor contributor_credentials\">Peter Itin, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/contributors\" class=\"contributor contributor_credentials\">Bettina Burger, DSc</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/contributors\" class=\"contributor contributor_credentials\">Jennifer L Hand, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/contributors\" class=\"contributor contributor_credentials\">Rosamaria Corona, MD, DSc</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jul 25, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H619572217\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Epidermodysplasia verruciformis (EV, MIM #226400) is a rare autosomal recessive skin disease characterized by an abnormally high susceptibility to infection with certain types of human papillomavirus (HPV) called EV-HPV, mostly beta-HPV [<a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/1-5\" class=\"abstract_t\">1-5</a>]. Patients have disseminated polymorphic lesions, including flat-topped, wart-like papules and pityriasis versicolor-like macules, predominantly on skin areas exposed to sunlight. In addition, patients with EV have an increased risk of developing nonmelanoma skin cancers, mainly cutaneous squamous cell carcinomas, at an early age [<a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/6-9\" class=\"abstract_t\">6-9</a>].</p><p>This topic will discuss the pathogenesis, clinical manifestations, diagnosis, and treatment of epidermodysplasia verruciformis. The epidemiology, virology, and natural history of HPV infection are discussed separately.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=human-papillomavirus-infections-epidemiology-and-disease-associations\" class=\"medical medical_review\">&quot;Human papillomavirus infections: Epidemiology and disease associations&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=virology-of-human-papillomavirus-infections-and-the-link-to-cancer\" class=\"medical medical_review\">&quot;Virology of human papillomavirus infections and the link to cancer&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H320236839\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The prevalence of epidermodysplasia verruciformis (EV) is not known. A total of 501 patients have been described worldwide; most cases are sporadic, but there are several reports of familial cases [<a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/10\" class=\"abstract_t\">10</a>].</p><p class=\"headingAnchor\" id=\"H619572223\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The pathogenesis of epidermodysplasia verruciformis (EV) is incompletely understood. It is thought to result from a combination of genetic factors leading to a selective immunodeficiency, infection from EV-HPVs, and exposure to UV radiation [<a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/11,12\" class=\"abstract_t\">11,12</a>].</p><p class=\"headingAnchor\" id=\"H619572229\"><span class=\"h2\">Genetics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>EV is inherited in an autosomal recessive fashion in most of the described families. Autosomal and X-linked inheritance have also been reported [<a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/13,14\" class=\"abstract_t\">13,14</a>]. Biallelic mutations in <em>TMC6</em> or <em>TMC8</em> (also named <em>EVER1</em> and <em>EVER2</em>) on chromosome 17q25.3 have been found in 25 patients from 17 families [<a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/11,15-25\" class=\"abstract_t\">11,15-25</a>]. All described mutations are loss-of-function mutations (nonsense, splice site, frameshift mutation, or exon deletion) and result in a lack of functional protein production [<a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/4\" class=\"abstract_t\">4</a>]. However, at least 25 percent of EV patients reveal no mutation in either of these genes, indicating nonallelic heterogeneity of the disease.</p><p class=\"headingAnchor\" id=\"H59702061\"><span class=\"h2\">Role of TMC6 and TMC8</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>TMC6 </em>and <em>TMC8 </em>belong to a larger gene family named transmembrane channel-like gene family, which consists of a group of highly conserved transmembrane proteins [<a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/26\" class=\"abstract_t\">26</a>]. Yeast two-hybrid screens and co-immunoprecipitation data suggest that both <em>TMC</em> genes form a complex with the zinc transporter ZnT-1 [<a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/22\" class=\"abstract_t\">22</a>]. This complex is located within the membrane of the endoplasmic reticulum [<a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/27\" class=\"abstract_t\">27</a>] and influences the zinc homeostasis in cells by decreasing Zn<sup>2+</sup> release from the endoplasmic reticulum [<a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/22,28\" class=\"abstract_t\">22,28</a>].</p><p>TMC6 and TMC8 proteins are involved in EV-HPV persistence and oncogenicity. It is hypothesized that the Zn<sup>2+</sup> level controlled by the <em>TMC</em><span class=\"nowrap\">/ZnT-1</span> complex leads to a reduced activity of transcription factors, which are essential for the replication of EV-HPVs. Due to the mutated and missing <em>TMC</em><span class=\"nowrap\">/ZnT-1</span> complex, the levels of the transcription factors increase and enable the EV-HPVs to replicate, leading to the EV phenotype [<a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/27\" class=\"abstract_t\">27</a>]. (See <a href=\"#H619572241\" class=\"local\">'HPV infection'</a> below.)</p><p>One study showed that <em>TMC8</em> supports tumor necrosis factor (TNF)-alpha-dependent apoptosis but prevents TNF-alpha-dependent NF-kB activation by interaction with TNF receptor-associated death domain protein (TRADD) [<a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/29\" class=\"abstract_t\">29</a>]. Epidermis samples of EV patients revealed an overexpression of transforming growth factor-beta-1 and TNF-alpha compared with samples of non-EV patients [<a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/30\" class=\"abstract_t\">30</a>].</p><p class=\"headingAnchor\" id=\"H59701863\"><span class=\"h2\">Immune system abnormalities</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although the number of CD4<sup>+</sup> and CD8<sup>+ </sup>T cells in EV patients appears to be normal, a significant increase in memory CD4<sup>+</sup> and effector memory CD8<sup>+</sup> T cells as well as an increase in skin-homing CD4<sup>+</sup> T cell subsets has been reported [<a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/31\" class=\"abstract_t\">31</a>]. Both <em>TMC6 </em>and <em>TMC8</em> are expressed in the skin and abundantly in T cells. Lymphoblastoid cells or primary T cells from EV patients have increased levels of Zn<sup>2+</sup> [<a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/32\" class=\"abstract_t\">32</a>]. A late-onset form of EV, named acquired EV, is reported in patients with primary immunodeficiencies and in patients with acquired cell-mediated immunodeficiency (HIV-positive patients and immunosuppressive treatment in organ transplant recipients) [<a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/33,34\" class=\"abstract_t\">33,34</a>]. (See <a href=\"#H3047030\" class=\"local\">'Acquired EV'</a> below.)</p><p class=\"headingAnchor\" id=\"H619572241\"><span class=\"h2\">HPV infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Infection from EV-HPV occurs during infancy [<a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/35\" class=\"abstract_t\">35</a>]. EV patients are susceptible to skin infections by particular types of HPV predominantly belonging to the genus beta (EV-HPV), which are considered to be nonpathogenic to the general population (<a href=\"image.htm?imageKey=DERM%2F102332\" class=\"graphic graphic_table graphicRef102332 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/12,36\" class=\"abstract_t\">12,36</a>]. In contrast to other HPVs, EV-HPVs do not integrate into the human genome and do not have the HPV gene <em>E5</em>, encoding a protein that interacts, among others, with the zinc transporter ZnT-1. It is hypothesized that due to the missing <em>E5</em> the general population is enabled to suppress the invasion of EV-HPV. Patients with EV are not able to eliminate EV-HPV-harboring keratinocytes due to impaired Zn<sup>2+</sup> homeostasis [<a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/22,27\" class=\"abstract_t\">22,27</a>]. (See <a href=\"#H59702061\" class=\"local\">'Role of TMC6 and TMC8'</a> above.)</p><p class=\"headingAnchor\" id=\"H59701806\"><span class=\"h2\">Skin cancer</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Over 60 percent of EV patients develop cutaneous squamous cell carcinoma (SCC), including SCC in situ (Bowen's disease), at an early age. Basal cell carcinomas and keratoacanthomas have also been reported [<a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/37\" class=\"abstract_t\">37</a>].</p><p>Cutaneous SCCs arise almost exclusively in sun-exposed skin areas and in approximately 90 percent harbor EV-HPV type 5 and type 8, both expressing the oncoproteins E6 and E7 [<a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/38\" class=\"abstract_t\">38</a>]. However, the E6 and E7 proteins of most EV-HPVs do not have the transforming potential of E6 and E7 proteins of high-risk genital alpha-type HPVs (HPV16 and HPV18) [<a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/39\" class=\"abstract_t\">39</a>]. (See <a href=\"topic.htm?path=virology-of-human-papillomavirus-infections-and-the-link-to-cancer\" class=\"medical medical_review\">&quot;Virology of human papillomavirus infections and the link to cancer&quot;</a>.)</p><p>These observations suggest that multiple factors are involved in the pathogenesis of cutaneous SCC in EV patients, including direct damage of keratinocyte DNA from UV radiation, inhibition of UVB-induced keratinocyte apoptosis by HPV, activation of HPV promotors by UVB [<a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/40\" class=\"abstract_t\">40</a>], and UV-induced local immunosuppression [<a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/38\" class=\"abstract_t\">38</a>].</p><p class=\"headingAnchor\" id=\"H619572253\"><span class=\"h1\">PATHOLOGY</span></p><p class=\"headingAnchor\" id=\"H619572260\"><span class=\"h2\">Histopathology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The histopathology of EV-lesions, also called EV-plane warts, demonstrates basket-weave hyperkeratosis, mild acanthosis, and vacuolated cells in the upper epidermis (<a href=\"image.htm?imageKey=DERM%2F102289\" class=\"graphic graphic_picture graphicRef102289 \">picture 1</a>). The nuclei can be pyknotic and may be surrounded by clear halos. The cytoplasm of affected cells stains pale blue and contains numerous round basophilic keratohyalin granules.</p><p class=\"headingAnchor\" id=\"H619572266\"><span class=\"h2\">HPV detection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>EV-HPV can be detected in all EV patients in lesional skin and in plucked eyebrow hairs by polymerase chain reaction and direct sequencing. (See <a href=\"topic.htm?path=virology-of-human-papillomavirus-infections-and-the-link-to-cancer#H11\" class=\"medical medical_review\">&quot;Virology of human papillomavirus infections and the link to cancer&quot;, section on 'Detecting HPV'</a>.) </p><p>Multiple HPV types, including some alpha-types with uncertain correlation with EV, are usually present in the same patient (<a href=\"image.htm?imageKey=DERM%2F102332\" class=\"graphic graphic_table graphicRef102332 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/41-43\" class=\"abstract_t\">41-43</a>]. Approximately 90 percent of cutaneous SCCs occurring in EV patients harbor HPV types 5 or 8.</p><p class=\"headingAnchor\" id=\"H619572272\"><span class=\"h2\">Immunohistochemistry</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>An analysis of specific epidermal markers (KRT1, 10, 14, 16, 4, involucrin, filaggrin, and E-cadherin) in EV lesions demonstrated diminished expression of K1 and K10, which were replaced by K14, reflecting immaturity and lack of differentiation in the abnormal epidermis [<a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/44\" class=\"abstract_t\">44</a>]. In addition, K16 and K4, normally not found in the differentiated epidermis, as well as involucrin were overexpressed in the spinous layer, suggesting disturbed proliferation and differentiation of the epidermal cells. Such alterations could be induced by the <em>E7</em> gene of some HPV types [<a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/45\" class=\"abstract_t\">45</a>].</p><p class=\"headingAnchor\" id=\"H320237064\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Individuals with EV usually develop multiple polymorphic skin lesions during early infancy or childhood. In many patients, the clinical appearance of the lesions does not immediately suggest verruca. Lesions may present as flat-topped papular lesions similar to verrucae planae on the extremities (<a href=\"image.htm?imageKey=DERM%2F102317\" class=\"graphic graphic_picture graphicRef102317 \">picture 2</a>) or as red or red-brownish plaques or pityriasis versicolor-like lesions mostly distributed on the trunk, neck, and face (<a href=\"image.htm?imageKey=DERM%2F102288\" class=\"graphic graphic_picture graphicRef102288 \">picture 3</a>). Some patients may present verruca-like papillomatous lesions or seborrheic keratosis-like lesions [<a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/46,47\" class=\"abstract_t\">46,47</a>]. </p><p>Data on the clinical course of EV lesions are lacking. In the authors' experience, the clinical phenotype of a specific skin area may change and spontaneous regression or progression may occur. </p><p>EV patients are not reported to have an increased susceptibility to infection from HPV types causing cutaneous warts, anogenital warts, or cervical, anal, or penile cancer. (See <a href=\"topic.htm?path=cutaneous-warts-common-plantar-and-flat-warts\" class=\"medical medical_review\">&quot;Cutaneous warts (common, plantar, and flat warts)&quot;</a> and <a href=\"topic.htm?path=condylomata-acuminata-anogenital-warts-in-adults-epidemiology-pathogenesis-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Condylomata acuminata (anogenital warts) in adults: Epidemiology, pathogenesis, clinical features, and diagnosis&quot;</a> and <a href=\"topic.htm?path=virology-of-human-papillomavirus-infections-and-the-link-to-cancer\" class=\"medical medical_review\">&quot;Virology of human papillomavirus infections and the link to cancer&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H288191\"><span class=\"h2\">Skin cancer</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Approximately two-thirds of EV patients develop actinic keratoses and cutaneous squamous cell carcinoma (SCC), including Bowen-type carcinoma in situ, at an early age, usually in the second or third decade of life [<a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/48,49\" class=\"abstract_t\">48,49</a>]. There is no known relationship between EV phenotypes and risk of skin cancer. (See <a href=\"topic.htm?path=epidemiology-and-risk-factors-for-cutaneous-squamous-cell-carcinoma#H22\" class=\"medical medical_review\">&quot;Epidemiology and risk factors for cutaneous squamous cell carcinoma&quot;, section on 'HPV infection'</a>.)</p><p class=\"headingAnchor\" id=\"H59702091\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of EV is suspected in a patient with a history of multiple diffuse, flat, wart-like skin lesions beginning in infancy or early childhood. The definitive diagnosis requires a skin biopsy and is based upon the histologic finding of hyperkeratosis, mild acanthosis, and vacuolated cells in the upper epidermis and demonstration of HPV in the skin lesion. HPV DNA testing is performed in specialized laboratories. (See <a href=\"#H619572260\" class=\"local\">'Histopathology'</a> above and <a href=\"topic.htm?path=virology-of-human-papillomavirus-infections-and-the-link-to-cancer#H11\" class=\"medical medical_review\">&quot;Virology of human papillomavirus infections and the link to cancer&quot;, section on 'Detecting HPV'</a>.)</p><p>Mutational analysis of <em>TMC6</em> and <em>TMC8</em> is not routinely performed in patients with EV. Mutations can be identified in only 75 percent of all EV patients.</p><p class=\"headingAnchor\" id=\"H619572303\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis of EV includes:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Confluent and reticulated papillomatosis of Gougerot and Carteaud</strong> &ndash; Confluent and reticulated papillomatosis of Gougerot and Carteaud is an uncommon cutaneous disorder of unknown etiology usually occurring in young adults [<a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/50\" class=\"abstract_t\">50</a>]. It presents with hyperpigmented, scaly patches with a reticulated appearance on the chest and upper back (<a href=\"image.htm?imageKey=DERM%2F67566%7EDERM%2F76296%7EDERM%2F54172%7EDERM%2F66671\" class=\"graphic graphic_picture graphicRef67566 graphicRef76296 graphicRef54172 graphicRef66671 \">picture 4A-D</a>). Histology shows hyperkeratosis, acanthosis, and papillomatosis; HPV is absent. (See <a href=\"topic.htm?path=acquired-hyperpigmentation-disorders#H469107941\" class=\"medical medical_review\">&quot;Acquired hyperpigmentation disorders&quot;, section on 'Confluent and reticulated papillomatosis'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Pityriasis versicolor</strong> &ndash; Pityriasis versicolor is a common superficial fungal infection presenting with hypopigmented, hyperpigmented, or erythematous macules on the trunk and proximal upper extremities (<a href=\"image.htm?imageKey=DERM%2F52438\" class=\"graphic graphic_picture graphicRef52438 \">picture 5</a> and <a href=\"image.htm?imageKey=PC%2F59533\" class=\"graphic graphic_picture graphicRef59533 \">picture 6</a>). A potassium hydroxide (KOH) preparation showing both hyphae and yeast cells confirms the diagnosis. (See <a href=\"topic.htm?path=tinea-versicolor-pityriasis-versicolor\" class=\"medical medical_review\">&quot;Tinea versicolor (Pityriasis versicolor)&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Disseminated superficial porokeratosis</strong> &ndash; Disseminated superficial porokeratosis (DSAP) is a disorder of keratinization characterized by small erythematous, skin-colored, or hyperpigmented macules with a fine peripheral keratotic ridge (<a href=\"image.htm?imageKey=DERM%2F59742%7EDERM%2F81874%7EDERM%2F80248\" class=\"graphic graphic_picture graphicRef59742 graphicRef81874 graphicRef80248 \">picture 7A-C</a>). Histology shows the pathognomonic cornoid lamella, a thin column of tightly packed parakeratotic cells. (See <a href=\"topic.htm?path=porokeratosis\" class=\"medical medical_review\">&quot;Porokeratosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Darier disease</strong> &ndash; Darier disease is a rare genodermatosis characterized by a persistent eruption of greasy hyperkeratotic papules in seborrheic areas such as forehead, scalp, chest, and back (<a href=\"image.htm?imageKey=DERM%2F70000%7EDERM%2F56168%7EDERM%2F86186%7EDERM%2F86187%7EDERM%2F86188\" class=\"graphic graphic_picture graphicRef70000 graphicRef56168 graphicRef86186 graphicRef86187 graphicRef86188 \">picture 8A-E</a>). Some patients may have warty, flat-topped papules on the dorsa of the hands and feet that are clinically indistinguishable from similar lesions occurring in EV. The histologic finding of acantholysis and dyskeratosis can clarify the diagnosis. (See <a href=\"topic.htm?path=darier-disease\" class=\"medical medical_review\">&quot;Darier disease&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Flat warts</strong> &ndash; Flat warts (verrucae planae) are minimally elevated, flat-topped, skin-colored papules caused by HPV types 3, 10, and 28, commonly occurring on the face, neck, and legs (<a href=\"image.htm?imageKey=DERM%2F72086%7EDERM%2F51139\" class=\"graphic graphic_picture graphicRef72086 graphicRef51139 \">picture 9A-B</a>). They are histologically indistinguishable from EV lesions. In contrast to EV, flat warts may disappear spontaneously in months to years. (See <a href=\"topic.htm?path=cutaneous-warts-common-plantar-and-flat-warts\" class=\"medical medical_review\">&quot;Cutaneous warts (common, plantar, and flat warts)&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H619572315\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are no curative therapies for EV. Systemic retinoids, including <a href=\"topic.htm?path=acitretin-drug-information\" class=\"drug drug_general\">acitretin</a> and <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a>, have been used in a few patients with transient benefit [<a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/51-54\" class=\"abstract_t\">51-54</a>]. Treatment of EV lesions with topical <a href=\"topic.htm?path=imiquimod-drug-information\" class=\"drug drug_general\">imiquimod</a> has been reported in a few patients with inconsistent results [<a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/20,55-58\" class=\"abstract_t\">20,55-58</a>]. There are isolated reports of successful use of photodynamic therapy [<a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/59\" class=\"abstract_t\">59</a>] and topical 5-fluorouracil [<a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/52\" class=\"abstract_t\">52</a>]. Recurrence is usual when treatment is discontinued. High-dose oral <a href=\"topic.htm?path=cimetidine-drug-information\" class=\"drug drug_general\">cimetidine</a> has been used in a few patients with inconsistent results [<a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/60,61\" class=\"abstract_t\">60,61</a>].</p><p>Patients should be educated to adopt strict sun protection measures to prevent the development of actinic keratoses and nonmelanoma skin cancer. (See <a href=\"topic.htm?path=selection-of-sunscreen-and-sun-protective-measures\" class=\"medical medical_review\">&quot;Selection of sunscreen and sun-protective measures&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3046138\"><span class=\"h2\">SCC management</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Cryotherapy is an appropriate first-line treatment for of actinic keratoses, Bowen's disease (cutaneous squamous cell carcinoma [SCC] in situ), and low-risk invasive cutaneous SCCs in patients with EV. Surgical excision is appropriate for both low-risk SCC and for SCC at increased risk of recurrence. (See <a href=\"topic.htm?path=treatment-and-prognosis-of-cutaneous-squamous-cell-carcinoma\" class=\"medical medical_review\">&quot;Treatment and prognosis of cutaneous squamous cell carcinoma&quot;</a>.)</p><p>Treatment of SCC with radiotherapy in EV patients has been associated with aggressive tumor recurrence and should be avoided [<a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/62,63\" class=\"abstract_t\">62,63</a>].</p><p class=\"headingAnchor\" id=\"H59703432\"><span class=\"h1\">FOLLOW-UP</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with EV should undergo lifelong regular skin examination for early diagnosis and treatment of precancerous skin lesions and skin cancer. Patients without malignant tumors should be seen annually by a dermatologist. More frequent skin examinations at three- to six-month intervals may be necessary for patients treated for invasive SCC. Approximately 70 to 80 percent of recurrences or metastases of cutaneous SCC occur within two years after therapy, and approximately 95 percent occur within five years. (See <a href=\"topic.htm?path=recognition-and-management-of-high-risk-aggressive-cutaneous-squamous-cell-carcinoma\" class=\"medical medical_review\">&quot;Recognition and management of high-risk (aggressive) cutaneous squamous cell carcinoma&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3047030\"><span class=\"h1\">ACQUIRED EV</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A late-onset form of EV has been reported in patients with impaired cell-mediated immunity and termed &quot;acquired EV&quot; [<a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/33\" class=\"abstract_t\">33</a>]. Most patients with acquired EV are solid organ transplant recipients or patients with human immunodeficiency virus (HIV) infection [<a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/64-68\" class=\"abstract_t\">64-68</a>]. There are single-case reports of EV occurring in patients with lepromatous leprosy [<a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/69\" class=\"abstract_t\">69</a>], Hodgkin lymphoma [<a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/70\" class=\"abstract_t\">70</a>], and systemic lupus erythematosus [<a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/71\" class=\"abstract_t\">71</a>].</p><p>Patients with acquired EV lack homozygous or compound heterozygous mutations in the <em>TMC6 </em>or <em>TMC8 </em>genes. Single-nucleotide polymorphism (SNP) variations in <em>TMC</em> have been reported in HIV-infected patients but not in transplant patients, suggesting a possible modulator function of SNPs in the development of acquired EV [<a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/65,66,72\" class=\"abstract_t\">65,66,72</a>].</p><p>The clinical and histopathological manifestations of EV are similar in inherited and acquired EV.&nbsp;Patients with acquired EV may present with diffuse xerosis as well as individual or coalescent flat-topped or hyperkeratotic papules.</p><p>Histologic examination of acquired EV lesions reveals the typical blue cells with pallor and a mild acanthosis similar to lesions of inherited EV. The demonstration of beta-HPV types 5 and 8 (or others) in skin lesions confirms the diagnosis of acquired EV.</p><p>For patients with acquired EV, treatments are directed at reducing the immunosuppression or treating the underlying primary disease. However, in patients with HIV-associated acquired EV, improvement in cell counts after institution of antiretroviral therapy does not appear to affect the course of EV. Management and monitoring of the skin lesions is similar to inherited EV.</p><p class=\"headingAnchor\" id=\"H151024507\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Epidermodysplasia verruciformis (EV) is a rare autosomal recessive skin disease characterized by an abnormally high susceptibility to infection with certain types of human papillomavirus (HPV) called EV-HPV, and increased risk of nonmelanoma skin cancer. (See <a href=\"#H619572217\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Individuals with EV usually develop during early infancy or childhood flat-topped papular lesions similar to verrucae planae on the extremities (<a href=\"image.htm?imageKey=DERM%2F102317\" class=\"graphic graphic_picture graphicRef102317 \">picture 2</a>) or red-brownish plaques or pityriasis versicolor-like lesions on the trunk, neck, and face (<a href=\"image.htm?imageKey=DERM%2F102288\" class=\"graphic graphic_picture graphicRef102288 \">picture 3</a>). (See <a href=\"#H320237064\" class=\"local\">'Clinical manifestations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Approximately two-thirds of EV patients develop actinic keratoses and cutaneous squamous cell carcinoma (SCC), including Bowen-type carcinoma in situ, at an early age, usually in the second or third decade of life. (See <a href=\"#H288191\" class=\"local\">'Skin cancer'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of EV requires a skin biopsy and is based upon the histologic features and demonstration of HPV in a skin lesion. (See <a href=\"#H59702091\" class=\"local\">'Diagnosis'</a> above and <a href=\"topic.htm?path=virology-of-human-papillomavirus-infections-and-the-link-to-cancer#H11\" class=\"medical medical_review\">&quot;Virology of human papillomavirus infections and the link to cancer&quot;, section on 'Detecting HPV'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A late-onset form of EV termed &quot;acquired EV&quot; has been reported in patients with impaired cell-mediated immunity, such as solid organ transplant recipients or patients with human immunodeficiency virus infection. (See <a href=\"#H3047030\" class=\"local\">'Acquired EV'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>There are no curative therapies for EV. Systemic retinoids have been used with transient benefit in a few patients. Patients should be educated to adopt strict sun protection measures to prevent the development of nonmelanoma skin cancer. (See <a href=\"#H619572315\" class=\"local\">'Treatment'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with EV should undergo lifelong regular skin examination for early diagnosis and treatment of precancerous skin lesions and skin cancer. (See <a href=\"#H59703432\" class=\"local\">'Follow-up'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/1\" class=\"nounderline abstract_t\">Lewandowsky F, Lutz W. [A case of a previously undescribed skin disease (epidermodysplasia verruciformis)]. Arch Dermatol Syph 1922; 141:193.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/2\" class=\"nounderline abstract_t\">JABLONSKA S, MILEWSKI B. [Information on epidermodysplasia verruciformis Lewandowsky-Lutz; positive results of auto- and heteroinoculation]. Dermatologica 1957; 115:1.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/3\" class=\"nounderline abstract_t\">Orth G, Jablonska S, Favre M, et al. Characterization of two types of human papillomaviruses in lesions of epidermodysplasia verruciformis. Proc Natl Acad Sci U S A 1978; 75:1537.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/4\" class=\"nounderline abstract_t\">Burger B, Itin PH. Epidermodysplasia verruciformis. Curr Probl Dermatol 2014; 45:123.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/5\" class=\"nounderline abstract_t\">Zahir A, Craig L, Rady P, et al. Epidermodysplasia verruciformis associated with HPV 10. Dermatol Online J 2013; 19:2.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/6\" class=\"nounderline abstract_t\">Lutzner MA. Epidermodysplasia verruciformis. An autosomal recessive disease characterized by viral warts and skin cancer. A model for viral oncogenesis. Bull Cancer 1978; 65:169.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/7\" class=\"nounderline abstract_t\">Majewski S, Jab&#322;o&#324;ska S. Epidermodysplasia verruciformis as a model of human papillomavirus-induced genetic cancer of the skin. Arch Dermatol 1995; 131:1312.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/8\" class=\"nounderline abstract_t\">Rajagopalan K, Bahru J, Loo DS, et al. Familial epidermodysplasia verruciformis of Lewandowsky and Lutz. Arch Dermatol 1972; 105:73.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/9\" class=\"nounderline abstract_t\">Quint KD, Genders RE, de Koning MN, et al. Human Beta-papillomavirus infection and keratinocyte carcinomas. J Pathol 2015; 235:342.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/10\" class=\"nounderline abstract_t\">Imahorn E, Y&uuml;ksel Z, Spoerri I, et al. Novel TMC8 splice site mutation in epidermodysplasia verruciformis and review of HPV infections in patients with the disease. J Eur Acad Dermatol Venereol 2017; 31:1722.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/11\" class=\"nounderline abstract_t\">Ramoz N, Rueda LA, Bouadjar B, et al. Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis. Nat Genet 2002; 32:579.</a></li><li class=\"breakAll\">Orth G. Epidermodysplasia verruciformis. In: The Papovaviridae--The Papillomaviruses, 1st ed, Salzman NP, Howley PM (Eds), Plenum Press, New York 1987. Vol 2, p.199.</li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/13\" class=\"nounderline abstract_t\">Androphy EJ, Dvoretzky I, Lowy DR. X-linked inheritance of epidermodysplasia verruciformis. Genetic and virologic studies of a kindred. Arch Dermatol 1985; 121:864.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/14\" class=\"nounderline abstract_t\">McDermott DF, Gammon B, Snijders PJ, et al. Autosomal dominant epidermodysplasia verruciformis lacking a known EVER1 or EVER2 mutation. Pediatr Dermatol 2009; 26:306.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/15\" class=\"nounderline abstract_t\">Tate G, Suzuki T, Kishimoto K, Mitsuya T. Novel mutations of EVER1/TMC6 gene in a Japanese patient with epidermodysplasia verruciformis. J Hum Genet 2004; 49:223.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/16\" class=\"nounderline abstract_t\">Sun XK, Chen JF, Xu AE. A homozygous nonsense mutation in the EVER2 gene leads to epidermodysplasia verruciformis. Clin Exp Dermatol 2005; 30:573.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/17\" class=\"nounderline abstract_t\">Zuo YG, Ma D, Zhang Y, et al. Identification of a novel mutation and a genetic polymorphism of EVER1 gene in two families with epidermodysplasia verruciformis. J Dermatol Sci 2006; 44:153.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/18\" class=\"nounderline abstract_t\">Gober MD, Rady PL, He Q, et al. Novel homozygous frameshift mutation of EVER1 gene in an epidermodysplasia verruciformis patient. J Invest Dermatol 2007; 127:817.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/19\" class=\"nounderline abstract_t\">Aochi S, Nakanishi G, Suzuki N, et al. A novel homozygous mutation of the EVER1/TMC6 gene in a Japanese patient with epidermodysplasia verruciformis. Br J Dermatol 2007; 157:1265.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/20\" class=\"nounderline abstract_t\">Berthelot C, Dickerson MC, Rady P, et al. Treatment of a patient with epidermodysplasia verruciformis carrying a novel EVER2 mutation with imiquimod. J Am Acad Dermatol 2007; 56:882.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/21\" class=\"nounderline abstract_t\">Rady PL, De Oliveira WR, He Q, et al. Novel homozygous nonsense TMC8 mutation detected in patients with epidermodysplasia verruciformis from a Brazilian family. Br J Dermatol 2007; 157:831.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/22\" class=\"nounderline abstract_t\">Lazarczyk M, Pons C, Mendoza JA, et al. Regulation of cellular zinc balance as a potential mechanism of EVER-mediated protection against pathogenesis by cutaneous oncogenic human papillomaviruses. J Exp Med 2008; 205:35.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/23\" class=\"nounderline abstract_t\">Landini MM, Zavattaro E, Borgogna C, et al. Lack of EVER2 protein in two epidermodysplasia verruciformis patients with skin cancer presenting previously unreported homozygous genetic deletions in the EVER2 gene. J Invest Dermatol 2012; 132:1305.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/24\" class=\"nounderline abstract_t\">Sunohara M, Ozawa T, Morimoto K, et al. Dye laser photodynamic therapy for Bowen's disease in a patient with epidermodysplasia verruciformis. Osaka City Med J 2012; 58:77.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/25\" class=\"nounderline abstract_t\">Mizuno Y, Kato G, Shu E, et al. Merkel cell polyomavirus-positive Merkel cell carcinoma in a patient with epidermodysplasia verruciformis. Acta Derm Venereol 2015; 95:98.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/26\" class=\"nounderline abstract_t\">Kurima K, Yang Y, Sorber K, Griffith AJ. Characterization of the transmembrane channel-like (TMC) gene family: functional clues from hearing loss and epidermodysplasia verruciformis. Genomics 2003; 82:300.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/27\" class=\"nounderline abstract_t\">Lazarczyk M, Cassonnet P, Pons C, et al. The EVER proteins as a natural barrier against papillomaviruses: a new insight into the pathogenesis of human papillomavirus infections. Microbiol Mol Biol Rev 2009; 73:348.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/28\" class=\"nounderline abstract_t\">Sirianant L, Ousingsawat J, Tian Y, et al. TMC8 (EVER2) attenuates intracellular signaling by Zn2+ and Ca2+ and suppresses activation of Cl- currents. Cell Signal 2014; 26:2826.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/29\" class=\"nounderline abstract_t\">Gaud G, Guillemot D, Jacob Y, et al. EVER2 protein binds TRADD to promote TNF-&alpha;-induced apoptosis. Cell Death Dis 2013; 4:e499.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/30\" class=\"nounderline abstract_t\">Majewski S, Hunzelmann N, Nischt R, et al. TGF beta-1 and TNF alpha expression in the epidermis of patients with epidermodysplasia verruciformis. J Invest Dermatol 1991; 97:862.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/31\" class=\"nounderline abstract_t\">Crequer A, Picard C, Pedergnana V, et al. EVER2 deficiency is associated with mild T-cell abnormalities. J Clin Immunol 2013; 33:14.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/32\" class=\"nounderline abstract_t\">Lazarczyk M, Dalard C, Hayder M, et al. EVER proteins, key elements of the natural anti-human papillomavirus barrier, are regulated upon T-cell activation. PLoS One 2012; 7:e39995.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/33\" class=\"nounderline abstract_t\">Rogers HD, Macgregor JL, Nord KM, et al. Acquired epidermodysplasia verruciformis. J Am Acad Dermatol 2009; 60:315.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/34\" class=\"nounderline abstract_t\">Jacobelli S, Laude H, Carlotti A, et al. Epidermodysplasia verruciformis in human immunodeficiency virus-infected patients: a marker of human papillomavirus-related disorders not affected by antiretroviral therapy. Arch Dermatol 2011; 147:590.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/35\" class=\"nounderline abstract_t\">Antonsson A, Karanfilovska S, Lindqvist PG, Hansson BG. General acquisition of human papillomavirus infections of skin occurs in early infancy. J Clin Microbiol 2003; 41:2509.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/36\" class=\"nounderline abstract_t\">Boxman IL, Mulder LH, Russell A, et al. Human papillomavirus type 5 is commonly present in immunosuppressed and immunocompetent individuals. Br J Dermatol 1999; 141:246.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/37\" class=\"nounderline abstract_t\">Mitsuishi T, Ohara K, Suzuki T, et al. Epidermodysplasia verruciformis with keratoacanthoma, Bowen's disease and squamous cell carcinoma: isolation of high-risk types of HPV 5 and unknown type of human papillomavirus. J Eur Acad Dermatol Venereol 2008; 22:1126.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/38\" class=\"nounderline abstract_t\">Horton JS, Stokes AJ. The transmembrane channel-like protein family and human papillomaviruses: Insights into epidermodysplasia verruciformis and progression to squamous cell carcinoma. Oncoimmunology 2014; 3:e28288.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/39\" class=\"nounderline abstract_t\">Ghittoni R, Accardi R, Hasan U, et al. The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Genes 2010; 40:1.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/40\" class=\"nounderline abstract_t\">Akg&uuml;l B, Lemme W, Garc&iacute;a-Escudero R, et al. UV-B irradiation stimulates the promoter activity of the high-risk, cutaneous human papillomavirus 5 and 8 in primary keratinocytes. Arch Virol 2005; 150:145.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/41\" class=\"nounderline abstract_t\">Dell'Oste V, Azzimonti B, De Andrea M, et al. High beta-HPV DNA loads and strong seroreactivity are present in epidermodysplasia verruciformis. J Invest Dermatol 2009; 129:1026.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/42\" class=\"nounderline abstract_t\">Michael KM, Waterboer T, Pfister H, et al. Seroreactivity of 38 human papillomavirus types in epidermodysplasia verruciformis patients, relatives, and controls. J Invest Dermatol 2010; 130:841.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/43\" class=\"nounderline abstract_t\">Orth G. Host defenses against human papillomaviruses: lessons from epidermodysplasia verruciformis. Curr Top Microbiol Immunol 2008; 321:59.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/44\" class=\"nounderline abstract_t\">Barcelos AC, Sotto MN. Comparative analysis of the expression of cytokeratins (1, 10, 14, 16, 4), involucrin, filaggrin and e-cadherin in plane warts and epidermodysplasia verruciformis plane wart-type lesions. J Cutan Pathol 2009; 36:647.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/45\" class=\"nounderline abstract_t\">Westphal K, Akg&uuml;l B, Storey A, Nindl I. Cutaneous human papillomavirus E7 type-specific effects on differentiation and proliferation of organotypic skin cultures. Cell Oncol 2009; 31:213.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/46\" class=\"nounderline abstract_t\">Foong HB, Ibrahimi OA, Elpern DJ, et al. Multiple facial seborrheic keratosis-like lesions in a young woman with epidermodysplasia verruciformis. Int J Dermatol 2008; 47:476.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/47\" class=\"nounderline abstract_t\">Tomasini C, Aloi F, Pippione M. Seborrheic keratosis-like lesions in epidermodysplasia verruciformis. J Cutan Pathol 1993; 20:237.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/48\" class=\"nounderline abstract_t\">de Oliveira WR, Festa Neto C, Rady PL, Tyring SK. Clinical aspects of epidermodysplasia verruciformis. J Eur Acad Dermatol Venereol 2003; 17:394.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/49\" class=\"nounderline abstract_t\">Majewski S, Jablonska S. Skin autografts in epidermodysplasia verruciformis: human papillomavirus-associated cutaneous changes need over 20 years for malignant conversion. Cancer Res 1997; 57:4214.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/50\" class=\"nounderline abstract_t\">Huang W, Ong G, Chong WS. Clinicopathological and diagnostic characterization of confluent and reticulate papillomatosis of Gougerot and Carteaud: a retrospective study in a South-East Asian population. Am J Clin Dermatol 2015; 16:131.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/51\" class=\"nounderline abstract_t\">Rallis E, Papatheodorou G, Bimpakis E, et al. Systemic low-dose isotretinoin maintains remission status in epidermodysplasia verruciformis. J Eur Acad Dermatol Venereol 2008; 22:523.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/52\" class=\"nounderline abstract_t\">Vohra S, Sharma NL, Shanker V, et al. Autosomal dominant epidermodysplasia verruciformis: a clinicotherapeutic experience in two cases. Indian J Dermatol Venereol Leprol 2010; 76:557.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/53\" class=\"nounderline abstract_t\">Serarslan G, Balci DD, Homan S. Acitretin treatment in acrokeratosis verruciformis of Hopf. J Dermatolog Treat 2007; 18:123.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/54\" class=\"nounderline abstract_t\">Farro P, Zalaudek I, Ferrara G, et al. Unusual association between acrokeratosis verruciformis of Hopf and multiple keratoacanthomas. Successful therapy with acitretin. J Dtsch Dermatol Ges 2004; 2:440.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/55\" class=\"nounderline abstract_t\">Janssen K, Lucker GP, Houwing RH, van Rijssel R. Epidermodysplasia verruciformis: unsuccessful therapeutic approach with imiquimod. Int J Dermatol 2007; 46 Suppl 3:45.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/56\" class=\"nounderline abstract_t\">Yoshida R, Kato T, Kawase M, et al. Two sisters reveal autosomal recessive inheritance of epidermodysplasia verruciformis: a case report. BMC Dermatol 2014; 14:12.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/57\" class=\"nounderline abstract_t\">Nijhawan RI, Osei-Tutu A, Hugh JM. Sustained clinical resolution of acquired epidermodysplasia verruciformis in an immunocompromised patient after discontinuation of oral acitretin with topical imiquimod. J Drugs Dermatol 2013; 12:348.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/58\" class=\"nounderline abstract_t\">Heratizadeh A, V&ouml;lker B, Kupsch E, et al. [Successful symptomatic treatment of epidermodysplasia verruciformis with imiquimod 5% cream]. Hautarzt 2010; 61:1052.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/59\" class=\"nounderline abstract_t\">Karrer S, Szeimies RM, Abels C, et al. Epidermodysplasia verruciformis treated using topical 5-aminolaevulinic acid photodynamic therapy. Br J Dermatol 1999; 140:935.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/60\" class=\"nounderline abstract_t\">de Oliveira WR, Neto CF, Rivitti EA. The lack of a clinical effect of cimetidine in the treatment of epidermodysplasia verruciformis. J Am Acad Dermatol 2004; 50:e14; author reply e15.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/61\" class=\"nounderline abstract_t\">Micali G, Nasca MR, Dall'Oglio F, Musumeci ML. Cimetidine therapy for epidermodysplasia verruciformis. J Am Acad Dermatol 2003; 48:S9.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/62\" class=\"nounderline abstract_t\">de Oliveira WR, da Cruz Silva LL, Neto CF, Tyring S. Deleterious Effect of Radiation Therapy on Epidermodysplasia Verruciformis Patients. J Cutan Med Surg 2015; 19:416.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/63\" class=\"nounderline abstract_t\">Rajabi MT, Ghasemi H, Safizadeh M, et al. Conjunctival squamous cell carcinoma with intraocular invasion after radiotherapy in epidermodysplasia verruciformis. Can J Ophthalmol 2014; 49:e43.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/64\" class=\"nounderline abstract_t\">Kunishige JH, Hymes SR, Madkan V, et al. Epidermodysplasia verruciformis in the setting of graft-versus-host disease. J Am Acad Dermatol 2007; 57:S78.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/65\" class=\"nounderline abstract_t\">Hohenstein E, Rady PL, Hergersberg M, et al. Epidermodysplasia verruciformis in a HIV-positive patient homozygous for the c917A--&gt;T polymorphism in the TMC8/EVER2 gene. Dermatology 2009; 218:114.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/66\" class=\"nounderline abstract_t\">Burger B, Kind F, Spoerri I, et al. HIV-positive child with epidermodysplasia verruciformis-like lesions and homozygous mutation in TMC6. AIDS 2010; 24:2758.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/67\" class=\"nounderline abstract_t\">Morrison C, Eliezri Y, Magro C, Nuovo GJ. The histologic spectrum of epidermodysplasia verruciformis in transplant and AIDS patients. J Cutan Pathol 2002; 29:480.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/68\" class=\"nounderline abstract_t\">Mendes AD, Bittencourt Mde J, Moure ER, et al. Acquired epidermodysplasia verruciformis in a renal transplant recipient--case report. An Bras Dermatol 2014; 89:144.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/69\" class=\"nounderline abstract_t\">Prestes-Carneiro LE, Nai GA, Silva MG, et al. Clinical presentation of tuberculoid leprosy in an epidermodysplasia verruciformis patient. J Infect Dev Ctries 2012; 6:526.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/70\" class=\"nounderline abstract_t\">Gross G, Ellinger K, Roussaki A, et al. Epidermodysplasia verruciformis in a patient with Hodgkin's disease: characterization of a new papillomavirus type and interferon treatment. J Invest Dermatol 1988; 91:43.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/71\" class=\"nounderline abstract_t\">Holmes C, Chong AH, Tabrizi SN, et al. Epidermodysplasia verruciformis-like syndrome in association with systemic lupus erythematosus. Australas J Dermatol 2009; 50:44.</a></li><li><a href=\"https://www.uptodate.com/contents/epidermodysplasia-verruciformis/abstract/72\" class=\"nounderline abstract_t\">Burger B, Sp&ouml;rri I, Stegmann DA, et al. Risk of Cutaneous Squamous Cell Carcinoma Development in Renal Transplant Recipients Is Independent of TMC/EVER Alterations. Dermatology 2015; 231:245.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 15509 Version 8.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H151024507\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H619572217\" id=\"outline-link-H619572217\">INTRODUCTION</a></li><li><a href=\"#H320236839\" id=\"outline-link-H320236839\">EPIDEMIOLOGY</a></li><li><a href=\"#H619572223\" id=\"outline-link-H619572223\">PATHOGENESIS</a><ul><li><a href=\"#H619572229\" id=\"outline-link-H619572229\">Genetics</a></li><li><a href=\"#H59702061\" id=\"outline-link-H59702061\">Role of TMC6 and TMC8</a></li><li><a href=\"#H59701863\" id=\"outline-link-H59701863\">Immune system abnormalities</a></li><li><a href=\"#H619572241\" id=\"outline-link-H619572241\">HPV infection</a></li><li><a href=\"#H59701806\" id=\"outline-link-H59701806\">Skin cancer</a></li></ul></li><li><a href=\"#H619572253\" id=\"outline-link-H619572253\">PATHOLOGY</a><ul><li><a href=\"#H619572260\" id=\"outline-link-H619572260\">Histopathology</a></li><li><a href=\"#H619572266\" id=\"outline-link-H619572266\">HPV detection</a></li><li><a href=\"#H619572272\" id=\"outline-link-H619572272\">Immunohistochemistry</a></li></ul></li><li><a href=\"#H320237064\" id=\"outline-link-H320237064\">CLINICAL MANIFESTATIONS</a><ul><li><a href=\"#H288191\" id=\"outline-link-H288191\">Skin cancer</a></li></ul></li><li><a href=\"#H59702091\" id=\"outline-link-H59702091\">DIAGNOSIS</a></li><li><a href=\"#H619572303\" id=\"outline-link-H619572303\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H619572315\" id=\"outline-link-H619572315\">TREATMENT</a><ul><li><a href=\"#H3046138\" id=\"outline-link-H3046138\">SCC management</a></li></ul></li><li><a href=\"#H59703432\" id=\"outline-link-H59703432\">FOLLOW-UP</a></li><li><a href=\"#H3047030\" id=\"outline-link-H3047030\">ACQUIRED EV</a></li><li><a href=\"#H151024507\" id=\"outline-link-H151024507\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DERM/15509|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/102289\" class=\"graphic graphic_picture\">- Epidermodysplasia verruciformis histo</a></li><li><a href=\"image.htm?imageKey=DERM/102317\" class=\"graphic graphic_picture\">- Epidermodysplasia verruciformis hands</a></li><li><a href=\"image.htm?imageKey=DERM/102288\" class=\"graphic graphic_picture\">- Epidermodysplasia verruciformis neck</a></li><li><a href=\"image.htm?imageKey=DERM/67566\" class=\"graphic graphic_picture\">- Confluent and reticulated papillomatosis - back</a></li><li><a href=\"image.htm?imageKey=DERM/76296\" class=\"graphic graphic_picture\">- Confluent and reticulated papillomatosis - chest</a></li><li><a href=\"image.htm?imageKey=DERM/54172\" class=\"graphic graphic_picture\">- Confluent and reticulated papillomatosis - close view</a></li><li><a href=\"image.htm?imageKey=DERM/66671\" class=\"graphic graphic_picture\">- Confluent and reticulated papillomatosis</a></li><li><a href=\"image.htm?imageKey=DERM/52438\" class=\"graphic graphic_picture\">- Tinea versicolor chest 2</a></li><li><a href=\"image.htm?imageKey=PC/59533\" class=\"graphic graphic_picture\">- Tinea versicolor arm</a></li><li><a href=\"image.htm?imageKey=DERM/59742\" class=\"graphic graphic_picture\">- Disseminated superficial actinic porokeratosis - legs</a></li><li><a href=\"image.htm?imageKey=DERM/81874\" class=\"graphic graphic_picture\">- Disseminated superficial actinic porokeratosis</a></li><li><a href=\"image.htm?imageKey=DERM/80248\" class=\"graphic graphic_picture\">- Disseminated superficial actinic porokeratosis 2</a></li><li><a href=\"image.htm?imageKey=DERM/70000\" class=\"graphic graphic_picture\">- Darier disease - dark skin</a></li><li><a href=\"image.htm?imageKey=DERM/56168\" class=\"graphic graphic_picture\">- Darier disease - light skin</a></li><li><a href=\"image.htm?imageKey=DERM/86186\" class=\"graphic graphic_picture\">- Darier plaques</a></li><li><a href=\"image.htm?imageKey=DERM/86187\" class=\"graphic graphic_picture\">- Darier forehead</a></li><li><a href=\"image.htm?imageKey=DERM/86188\" class=\"graphic graphic_picture\">- Darier keratotic papule</a></li><li><a href=\"image.htm?imageKey=DERM/72086\" class=\"graphic graphic_picture\">- Flat warts forehead</a></li><li><a href=\"image.htm?imageKey=DERM/51139\" class=\"graphic graphic_picture\">- Flat warts linear</a></li></ul></li><li><div id=\"DERM/15509|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/102332\" class=\"graphic graphic_table\">- HPV types in EV</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=acquired-hyperpigmentation-disorders\" class=\"medical medical_review\">Acquired hyperpigmentation disorders</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=condylomata-acuminata-anogenital-warts-in-adults-epidemiology-pathogenesis-clinical-features-and-diagnosis\" class=\"medical medical_review\">Condylomata acuminata (anogenital warts) in adults: Epidemiology, pathogenesis, clinical features, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cutaneous-warts-common-plantar-and-flat-warts\" class=\"medical medical_review\">Cutaneous warts (common, plantar, and flat warts)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=darier-disease\" class=\"medical medical_review\">Darier disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-and-risk-factors-for-cutaneous-squamous-cell-carcinoma\" class=\"medical medical_review\">Epidemiology and risk factors for cutaneous squamous cell carcinoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=human-papillomavirus-infections-epidemiology-and-disease-associations\" class=\"medical medical_review\">Human papillomavirus infections: Epidemiology and disease associations</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=porokeratosis\" class=\"medical medical_review\">Porokeratosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=recognition-and-management-of-high-risk-aggressive-cutaneous-squamous-cell-carcinoma\" class=\"medical medical_review\">Recognition and management of high-risk (aggressive) cutaneous squamous cell carcinoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=selection-of-sunscreen-and-sun-protective-measures\" class=\"medical medical_review\">Selection of sunscreen and sun-protective measures</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=tinea-versicolor-pityriasis-versicolor\" class=\"medical medical_review\">Tinea versicolor (Pityriasis versicolor)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-and-prognosis-of-cutaneous-squamous-cell-carcinoma\" class=\"medical medical_review\">Treatment and prognosis of cutaneous squamous cell carcinoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=virology-of-human-papillomavirus-infections-and-the-link-to-cancer\" class=\"medical medical_review\">Virology of human papillomavirus infections and the link to cancer</a></li></ul></div></div>","javascript":null}